Rodrigo Dienstmann
罗德里戈·迪恩斯特曼
MD
Head, Oncology Data Science Group; Attending Medical Oncologist肿瘤数据科学组主任；肿瘤内科主治医师
👥Biography 个人简介
Rodrigo Dienstmann is a pioneering translational oncologist and computational biologist who has been instrumental in defining the molecular landscape of colorectal cancer, including co-development of the Consensus Molecular Subtypes (CMS) classification framework. His research group at VHIO focuses on leveraging multi-omic data and artificial intelligence to identify predictive biomarkers, with particular emphasis on HER2 amplification, ctDNA-based minimal residual disease detection, and molecularly stratified clinical trial design. He has shaped the field's understanding of how molecular subtypes correlate with prognosis and therapeutic sensitivity.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Consensus Molecular Subtypes (CMS) of Colorectal Cancer
Was a key contributor to the international CMS consortium that classified colorectal cancer into four robust molecular subtypes (CMS1–4), providing a clinically relevant framework adopted worldwide for stratified trial design and prognostic assessment.
HER2 Amplification as a Therapeutic Target
Led clinical and translational analyses establishing HER2 amplification as a distinct targetable alteration in RAS/RAF-wildtype mCRC, contributing to the development and regulatory approval of HER2-directed therapies (trastuzumab/pertuzumab, tucatinib/trastuzumab) in colorectal cancer.
ctDNA for MRD and Treatment Monitoring
Conducted prospective studies demonstrating the utility of circulating tumor DNA for minimal residual disease detection after resection of colorectal liver metastases and for early identification of resistance to targeted therapies in mCRC.
Representative Works 代表性著作
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Nature Reviews Cancer (2017)
Comprehensive review synthesizing the CMS framework, its biological underpinnings, and implications for prognosis and treatment stratification in colorectal cancer.
HER2 amplification and anti-HER2 therapy in RAS/RAF wildtype metastatic colorectal cancer: pooled analysis and clinical utility
Annals of Oncology (2022)
Pooled analysis of HER2-directed trials demonstrating meaningful response rates and supporting HER2 testing as routine practice in RAS/RAF-wildtype mCRC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗德里戈·迪恩斯特曼 的研究动态
Follow Rodrigo Dienstmann's research updates
留下邮箱，当我们发布与 Rodrigo Dienstmann（Vall d'Hebron Institute of Oncology (VHIO), Barcelona）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment